HomeCompareGBT vs SBUX

GBT vs SBUX: Dividend Comparison 2026

GBT yields 2.92% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $142.9K in total portfolio value
10 years
GBT
GBT
● Live price
2.92%
Share price
$68.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.1K
Annual income
$352.49
Full GBT calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — GBT vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBT + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBT
Annual income on $10K today (after 15% tax)
$248.21/yr
After 10yr DRIP, annual income (after tax)
$299.62/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $60,166.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBT + SBUX for your $10,000?

GBT: 50%SBUX: 50%
100% SBUX50/50100% GBT
Portfolio after 10yr
$95.6K
Annual income
$35,744.47/yr
Blended yield
37.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

GBT
Analyst Ratings
18
Buy
11
Hold
Consensus: Buy
Price Target
$60.38
-11.8% upside vs current
Range: $36.00 — $110.00
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBT buys
0
SBUX buys
0
No recent congressional trades found for GBT or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBTSBUX
Forward yield2.92%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$24.1K$167.0K
Annual income after 10y$352.49$71,136.45
Total dividends collected$3.2K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$60.38$104.00

Year-by-year: GBT vs SBUX ($10,000, DRIP)

YearGBT PortfolioGBT Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$10,992$292.01$11,121$420.68$129.00SBUX
2$12,061$299.98$12,548$648.40$487.00SBUX
3$13,213$307.63$14,440$1,013.98$1.2KSBUX
4$14,453$314.97$17,068$1,617.30$2.6KSBUX
5$15,787$321.98$20,912$2,649.52$5.1KSBUX
6$17,221$328.69$26,875$4,499.29$9.7KSBUX
7$18,761$335.08$36,771$8,014.12$18.0KSBUX
8$20,416$341.18$54,542$15,197.11$34.1KSBUX
9$22,192$346.98$89,602$31,242.49$67.4KSBUX
10$24,098$352.49$167,011$71,136.45$142.9KSBUX

GBT vs SBUX: Complete Analysis 2026

GBTStock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Full GBT Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this GBT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBT vs SCHDGBT vs JEPIGBT vs OGBT vs KOGBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.